Publications

1532TiP Zolbetuximab with gemcitabine+ nab-paclitaxel (GN) in first-line treatment of Claudin 18.2–positive metastatic pancreatic cancer (mPC): Phase II, open-label, randomized …

W Park, EM O'Reilly, CP Li, DY Oh, R Garcia-Carbonero, G Roth, ...

317P Targeted next generation sequencing (NGS) of cell free (cf) DNA in biliary tract cancer (BTC)

D Cowzer, K Seier, M Darmofal, P Shin, D Khalil, H Walch, J Shia, W Park, ...

323P NALIRIFOX versus nab-paclitaxel and gemcitabine (Gem+ NabP) in treatment-naïve patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): subgroup analysis of …

TM Mercade, RAP Cid, M Womack, AC Gracian, A Zervoudakis, ...

592 CD40 agonist mitazalimab combined with mFOLFIRINOX in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): updated efficacy and correlative biomarkers from …

KP Geboes, G Beatty, I Borbath, T Macarulla, A Lambert, P Cassier, ...

708 Chemoimmunotherapy (ChemoIO) as treatment for pancreatic neuroendocrine carcinoma: survival outcomes and immunogenomic analysis

D Moss, C O’Connor, Z Tarcan, T Kim, MA Perry, R Thummalapalli, ...

A multi-institutional randomized phase III trial of chemotherapy alone versus chemotherapy and ablative 5-fraction MRI-guided adaptive radiation therapy for locally advanced …

MD Chuong, JM Frakes, KE Mittauer, J Good, J Kim, D Chang, DW Kim, ...

Abstract A005: A multi-institutional randomized phase III trial of chemotherapy alone versus chemotherapy and ablative 5-fraction MRI-guided adaptive radiation therapy for …

MD Chuong, JM Frakes, KE Mittauer, J Good, J Kim, D Chang, DW Kim, ...

Abstract B042: Clinical and molecular characterization of Lynch syndrome-associated pancreas adenocarcinoma (PDAC)

E Harrold, CA O'Connor, D Lin, A Gazzo, H Walch, M Ranganathan, ...

Abstract B045: Deep genomic and single cell molecular profiles define immunogenic pancreatic cancer

W Park, S Umeda, C O'Connor, H Zhang, R Sharma, A Richards, Y Zhu, ...

Abstract B061: Phase 1b study of maintenance soluble beta-glucan (Odetiglucan) in combination with a CD40 agonistic monoclonal antibody (CDX-1140) in patients with metastatic …

MH O'Hara, M Wattenberg, I Garrido-Laguna, EM O'Reilly, M Yellin, ...

Abstract C074: Clinico-genomic characterization of N=2,460 pancreatic adenocarcinoma identifies KRASMUT dosage as prognostic of overall survival across …

AM Varghese, MA Perry, D Muldoon, S Nandakumar, A Erakky, B Nguyen, ...

Abstract C092: T cell responses and clinical outcomes in pancreatic and colorectal cancer patients with minimal residual disease in AMPLIFY-201, a phase 1 trial of a first-in …

ZA Wainberg, S Pant, CD Weekes, M Furqan, PM Kasi, CE Devoe, ...

Abstract C104: Dual primary pancreas cancers–Related or independent lesions?

JD Schoenfeld, H Sahan-Ozkan, N Bilani, MI D'Angelica, WR Jarnagin, ...

Abstract PR-06: Personalized RNA neoantigen vaccines induce long-lived CD8+ T effector cells in pancreatic cancer

P Guasp, Z Sethna, C Reiche, M Milighetti, N Ceglia, E Patterson, N Pang, ...

Abstract PR-17: Genomic and transcriptomic characterization of pancreatic cancer patients on the PASS-01 trial

GM O'Kane, G Jang, TJ Pugh, J Wilson, S Ramotar, DA King, D Laheru, ...

Adjuvant mFOLFIRINOX (mFFX) for resected pancreatic cancer (PC): Long term clinical and genomic outcomes.

F Keane, D Moss, CA O'Connor, M Perry, JF Chou, F Crowley, P Saxena, ...

Alliance A022101/NRG-GI009: A Pragmatic Randomized Phase III Trial Evaluating Total Ablative Therapy for Patients with Limited Metastatic Colorectal Cancer-Evaluating Radiation …

PB Romesser, ED Miller, Q Shi, JG Dixon, S Gholami, S White, C Wu, ...

Alliance A022101/NRG-GI009: A pragmatic randomized phase III trial evaluating total ablative therapy for patients with limited metastatic colorectal cancer—Evaluating …

ED Miller, K Hitchcock, Q Shi, JG Dixon, S Gholami, SB White, C Wu, ...

Alliance A022104/NRG-GI010: The Janus Rectal Cancer Trial: a randomized phase II/III trial testing the efficacy of triplet versus doublet chemotherapy regarding clinical …

JA Alvarez, Q Shi, A Dasari, J Garcia-Aguilar, H Sanoff, TJ George, ...

Alliance A022106: A phase II/III trial of NABPLAGEM vs nab-paclitaxel/gemcitabine as second-line treatment for BRCA1/2 or PALB2 mutant metastatic pancreatic …

ES Tsang, Q Shi, KP Olive, EA Collisson, JG Dixon, M Cusnir, R Winograd, ...

Alliance EAY191-A6: FOLFOX in combination with binimetinib as second-line therapy for patients with advanced biliary tract cancers (BTCs) with MAPK pathway …

A Shergill, CY Liao, MI Elsaid, T Al Baghdadi, Y Ji, D Feldman, S George, ...

Alliance for clinical trials in Oncology (Alliance) trial A022101/NRG-GI009: a pragmatic randomized phase III trial evaluating total ablative therapy for patients with limited …

KE Hitchcock, ED Miller, Q Shi, JG Dixon, S Gholami, SB White, C Wu, ...

AMPLIFY-7P, a first-in-human safety and efficacy trial of adjuvant mKRAS-specific lymph node targeted amphiphile ELI-002 7P vaccine in patients with minimal residual disease …

CE Devoe, S Pant, ZA Wainberg, V Chung, TJ George, PM Kasi, ...

AMPLIFY-7P: Phase 1 and randomized phase 2 study of amphiphile immunotherapy ELI-002 7P as adjuvant treatment for subjects with G12D, G12R, G12V, G12C, G12A, G12S and G13D …

ZA Wainberg, V Chung, CE Devoe, TJ George, E Welkowsky, T Kheoh, ...

ARC-8: Phase 1/1b randomized study of quemliclustat+ gemcitabine/nab-paclitaxel±zimberelimab in patients with treatment-naive metastatic pancreatic adenocarcinoma

ZA Wainberg, GA Manji, N Bahary, SV Ulahannan, S Pant, NV Uboha, ...

ASO Visual Abstract: Has Management of Intrahepatic Cholangiocarcinoma Evolved with the Evidence? Trends and Practice Patterns from the National Cancer Database

LE Schleimer, HL Kalvin, RJ Ellis, TP Kingham, KC Soares, MI D’Angelica, ...

Association of Sex and Obesity on Overall Survival in Patients Undergoing Upfront Surgery for Resectable Pancreatic Adenocarcinoma

SJ Judge, E Manin, J Chou, TP Kingham, VP Balachandran, ...

Automated real-world data integration improves cancer outcome prediction

Jee J, Fong C, Pichotta K, Tran TN, Luthra A, Waters M, Fu C, Altoe M, …

BNT321, a novel monoclonal antibody targeting sialyl Lewis A: Phase 1 monotherapy and combination with mFOLFIRINOX in patients with advanced CA19-9 expressing cancers.

EM O'Reilly, TM Bauer, EH Borazanci, M Pelster, AM Varghese, W Park, ...

Body mass index (BMI) as a prelude to hepatocellular carcinoma (HCC) and metabolic dysfunction–associated steatohepatitis (MASH) risk factors in patients with no identified …

L Al Mahmasani, M Capanu, A Srivastava, JF Chou, J Shia, IH El Dika, ...

CALGB 80802 (Alliance): Impact of Sorafenib with and without Doxorubicin on Hepatitis C Infection in Patients with Advanced Hepatocellular Carcinoma

Abou-Alfa GK, Geyer SM, Nixon AB, Innocenti F, Shi Q, Kumthekar P, Jacobson S, El Dika I, et al.

Chemotherapy switch for localized pancreatic cancer: a systematic review and meta-analysis

EN Dekker, RR Narayan, MA Ahmami, A Meddouch, EMM Verkolf, ...

Circulating KRAS G12D but not G12V is associated with survival in metastatic pancreatic ductal adenocarcinoma

Till JE, McDaniel L, Chang C, Long Q, Pfeiffer SM, Lyman JP, Padrón LJ, Maurer DM, et al.

Clinical and translational results from REVOLUTION cohorts A (nivolumab plus ipilimumab plus chemotherapy) and B (hydroxychloroquine plus ipilimumab plus chemotherapy) in …

EM O'Reilly, ZA Wainberg, GA Fisher Jr, RA Wolff, AH Ko, MH O'Hara, ...

Clinical and translational results from REVOLUTION cohorts A (nivolumab+ ipilimumab+ chemotherapy) and B (hydroxychloroquine+ ipilimumab+ chemotherapy) in patients with …

EM O'Reilly, ZA Wainberg, GA Fisher Jr, RA Wolff, AH Ko, MH O'Hara, ...

Clinico-genomic characterization of N= 2,460 pancreatic adenocarcinoma identifies KRASMUT dosage as prognostic of overall survival across disease stages

AM Varghese, MA Perry, D Muldoon, S Nandakumar, A Erakky, B Nguyen, ...

Clinicogenomic predictors of outcomes in patients with hepatocellular carcinoma treated with immunotherapy

D Cowzer, JF Chou, H Walch, F Keane, D Khalil, J Shia, RKG Do, ...

Concordance in Oncogenic Alterations Between the Primary Tumor and Advanced Disease: Insights Into the Heterogeneity of Intrahepatic Cholangiocarcinoma

McIntyre SM, Preston WA, Walch H, Sharib J, Kundra R, Sigel C, Lidsky ME, Allen PJ, et al.

Controversies in upper GI oncology: maintenance treatment in pancreatic cancer

J Dekervel, D Laheru, EM O’Reilly

Distinct clinical outcomes and biological features of specific KRAS mutants in human pancreatic cancer

McIntyre CA, Grimont A, Park J, Meng Y, Sisso WJ, Seier K, Jang GH, … Park W, …

Distinct genomic profiles are associated with minimal pathological response to preoperative hepatic artery infusion chemotherapy in initially unresectable colorectal liver …

N Nasar, J Datta, MT Evenhaim, J Chou, M Gonen, K Soares, ...

Does non-alcoholic fatty liver disease increase the risk for pancreatic cancer? A multi-center retrospective cohort study.

RR Singh, EM O'Reilly

Durvalumab and stereotactic ablative body radiotherapy (SABR) in locally advanced (LA) and borderline resectable (BR) pancreatic cancer (PDAC): Long-term outcomes and …

F Keane, R Tuli, CA O'Connor, C Schwartz, W Park, AM Varghese, ...

Early results of the PASS-01 trial: Pancreatic adenocarcinoma signature stratification for treatment-01.

JJ Knox, EM Jaffee, GM O'Kane, D King, D Laheru, KH Yu, K Perez, ...

Extrahepatic Cholangiocarcinoma: Genomic Variables Associated With Anatomic Location and Outcome

Preston WA, Drill E, Boerner T, Gelfer R, Harding JJ, O'Reilly EM, Cercek A, Abou-Alfa G, et al.

FEASIBILITY OF ENDOSCOPIC ULTRASOUND-GUIDED TISSUE ACQUISITION FOR NEXT-GENERATION SEQUENCING IN PANCREATIC CANCER PATIENTS

SE Lee, D Kim, M Schattner, V Rolston, E Vakiani, C Sigel, E O'Reilly, ...

Fibrolamellar carcinoma registry: Opportunities and challenges.

L Al Mahmasani, M Capanu, K Losert, MA Lowery, M Hennessy, M Ray, ...

FRONTIER: FAPi Radioligand OpeN-label, phase 1 study to evaluate safety, Tolerability and dosImetry of [Lu-177]-PNT6555; a dose Escalation study for tReatment of patients with …

D Juneau, P Kavan, U Metser, G Abikhzer, L Bodei, M Liberman, N Taunk, ...

Genomic predictors of response to hepatic artery pump chemotherapy in colorectal liver metastases

N Nasar, J Datta, MT Evenhaim, J Chou, M Gonen, K Soares, ...

Has management of intrahepatic cholangiocarcinoma evolved with the evidence? Trends and practice patterns from the National Cancer Database

LE Schleimer, HL Kalvin, RJ Ellis, TP Kingham, KC Soares, MI D’Angelica, ...